Acute hypoxia injury resistance use of teprenone

Abstract

The invention relates to the action of anti-acute hypoxia injury of teprenone, under the condition of oral administration of the teprenone, the survival ratio of chmice under the acute hypoxia condition can be obviously improved, the survival time can be prolonged. The invention pours the teprenone with different concentrations into the stomach of the adult chmice, after four hours, the chmice isarranged in the acute hypoxia environment, the survival ratio and the survival time are observed, so that the survival ratio of the animal can be improved and the survival time of the animal can be prolonged under acute hypoxia condition by pouring the teprenone with certain concentration into the stomach in advance, the anti-acute hypoxia injury capability of the chmice can be improved. According to the method of the invention, the teprenone is administrated at suitable time with suitable dose, which can improve the anti-acute hypoxia injury capability of the chmice, powerful evidences can be provided for the human body experiment, if the teprenone can be popularized for human body application, good economic benefit and social benefit can be generated.

Description

technical field [0001] The invention relates to an anti-acute hypoxic injury application of teprenone (digeranylacetone). Under the condition of oral administration, teprenone can significantly improve the survival rate and prolong the survival time of mice under acute hypoxic conditions. Background technique [0002] If human beings ascend rapidly to areas above 2500m without sufficient adaptation, acute mountain reaction often occurs, manifested as headache, anorexia, nausea, vomiting, fatigue, dizziness, insomnia, etc., which is clinically called acute mountain sickness (AMS) , if not treated, some patients may develop high-altitude pulmonary edema (HAPE) or high-altitude cerebral edema (high-altitude cerebral oedema, HACE). AMS and HACE are brain syndromes of high altitude sickness (high-alti-tude illness). It is generally believed that HACE is the late stage of AMS, with ataxia and altered consciousness as its clinical features, which may progress to coma or even death...

AI Technical Summary

Problems solved by technology

Whether teprenone can protect against acute hypoxic injury by inducing the expression of HSP70 has not been reported